Johnson & Johnson has raised its quarterly dividend for the sixty-fourth consecutive year, lifting the payout from $1.30 to $1.34 per share. The 3.1 percent increase, announced in April 2026 with a June 9 payment date, underscores why the healthcare giant remains a staple in conservative income portfolios even as broader markets navigate uncertainty.
The setup
Johnson & Johnson, trading under ticker JNJ on the NYSE, is one of only a handful of companies that qualifies as a Dividend King — an S&P 500 member with at least fifty consecutive years of payout increases. The new annualized dividend of $5.36 per share translates to a yield near 2.3 percent at recent prices. For conservative investors who prioritize stability over speculation, that reliability carries weight.
Key numbers
| Ticker | JNJ |
| Exchange | NYSE |
| Previous Dividend | $1.30 per quarter |
| New Dividend | $1.34 per quarter |
| Increase | 3.1% |
| Annualized Payout | $5.36 |
| Yield (approx) | 2.33% |
| Consecutive Increases | 64 years |
| Payment Date | June 9, 2026 |
| Q1 2026 Revenue | $24.06 billion (+9.9% YoY) |
| Q1 2026 Adjusted EPS | $2.70 |
What to watch
First-quarter revenue reached $24.06 billion, up 9.9 percent from the prior-year period. Adjusted earnings per share came in at $2.70. Standout performers included Darzalex at $3.96 billion, up 22.5 percent, and Tremfya at $1.61 billion, up 68.3 percent. Carvykti, the cell therapy treatment, contributed $597 million, rising 62.3 percent.
Management raised full-year 2026 revenue guidance to a range of $100.3 billion to $101.3 billion. Adjusted EPS guidance now sits between $11.45 and $11.65. The pharmaceutical segment, branded Innovative Medicine, continues to drive the bulk of growth while the MedTech division stabilizes.
For income investors, the key metric is not just the dividend yield but the payout ratio and cash flow coverage. Johnson & Johnson’s free cash flow generation historically covers the dividend multiple times over. That margin of safety is what separates sustainable dividend growers from yield traps.
Risks to watch
Patent cliffs remain a long-term concern for any pharmaceutical company. Johnson & Johnson faces biosimilar competition for several blockbuster drugs over the next decade. The company has addressed this through acquisitions and pipeline investment, but the transition is not without risk.
Talz sales and Stelara patent expirations in upcoming years could pressure revenue growth if pipeline replacements underperform. Additionally, the company continues to manage talc litigation overhang, though the recently proposed $9 billion settlement has reduced some uncertainty.
A retiree with $100,000 invested in JNJ at a 2.33 percent yield would generate roughly $2,330 in annual dividend income. At the pre-increase rate, that same position produced approximately $2,250. The $80 annual difference is modest, but compounded across 64 years of increases, the power of dividend growth becomes clear.
Bottom line
Johnson & Johnson remains one of the most dependable dividend growth stories in the large-cap healthcare space. The 64-year streak is not merely symbolic. It reflects a business model that generates predictable cash flows across pharmaceuticals, medical devices, and consumer health products. Conservative investors looking for sleep-well income should keep JNJ on their watch list.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
